Opioid Agonist Treatment and Safety (OATS) Study
Matthew Hickman, Bristol University
David Fiellin, Yale University
This project will use linked administrative data to understand risk for mortality and other adverse outcomes during and after opioid agonist treatment (OAT). It will use standard biostatistical approaches and sophisticated machine learning techniques.
North America is in the midst of an opioid use epidemic, and opioid use is also increasing dramatically in Australia. OAT is an effective treatment for opioid dependence, but there are important questions regarding risk of adverse clinical outcomes, including death, that are yet to be answered. Who is most at risk of adverse outcomes? What patient, provider and treatment setting actors may influence this risk? Answers to these and other questions are critical to inform the massive scale-up of OAT internationally that will be required to respond to the opioid epidemic.
Visit the NDARC website for more information.